{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Tablet&page=2", "query": { "intervention": "Oral Tablet", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Tablet&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-21T05:05:03.149Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05286788", "title": "MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adamantinous Craniopharyngioma", "Recurrent Adamantinomatous Craniopharyngioma" ], "interventions": [ { "name": "Binimetinib Oral Tablet [Mektovi]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "39 Years", "sex": "ALL", "summary": "1 Year to 39 Years" }, "enrollment_count": 38, "start_date": "2023-04-10", "completion_date": "2027-04-10", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-09-21T05:05:03.149Z", "location_count": 5, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05286788" }, { "nct_id": "NCT03374956", "title": "Individualized Obesity Pharmacotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Phentermine-Topiramate", "type": "DRUG" }, { "name": "Liraglutide", "type": "DRUG" }, { "name": "Naltrexone/bupropion", "type": "DRUG" }, { "name": "Phentermine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 193, "start_date": "2017-12-11", "completion_date": "2022-05-26", "has_results": true, "last_update_posted_date": "2023-07-18", "last_synced_at": "2026-09-21T05:05:03.149Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03374956" }, { "nct_id": "NCT04926831", "title": "Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "capmatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 4, "start_date": "2022-08-10", "completion_date": "2024-03-13", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-09-21T05:05:03.149Z", "location_count": 6, "location_summary": "La Jolla, California • Sacramento, California • Fairfax, Virginia", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04926831" }, { "nct_id": "NCT03227861", "title": "A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1" ], "interventions": [ { "name": "DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2017-07-31", "completion_date": "2019-09-04", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-09-21T05:05:03.149Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03227861" }, { "nct_id": "NCT07213973", "title": "Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa (HS)" ], "interventions": [ { "name": "Povorcitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 40, "start_date": "2026-02-02", "completion_date": "2028-03-25", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-21T05:05:03.149Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Farmington, Connecticut + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07213973" }, { "nct_id": "NCT04935294", "title": "Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Renal Dysfunction" ], "interventions": [ { "name": "Danicopan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 16, "start_date": "2018-01-24", "completion_date": "2018-05-29", "has_results": false, "last_update_posted_date": "2021-06-23", "last_synced_at": "2026-09-21T05:05:03.149Z", "location_count": 4, "location_summary": "Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04935294" }, { "nct_id": "NCT06835569", "title": "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "PDAC - Pancreatic Ductal Adenocarcinoma", "NSCLC (Non-small Cell Lung Cancer)", "CRC (Colorectal Cancer)", "Advanced Solid Tumors" ], "interventions": [ { "name": "ALTA3263", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed + Cisplatin /Carboplatin", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "GnP", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alterome Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 448, "start_date": "2025-03-05", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-09-21T05:05:03.149Z", "location_count": 12, "location_summary": "Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06835569" }, { "nct_id": "NCT03439254", "title": "Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Compensated Cirrhosis", "Nonalcoholic Steatohepatitis" ], "interventions": [ { "name": "Obeticholic acid (10 mg)", "type": "DRUG" }, { "name": "Obeticholic acid (10 mg to 25 mg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 919, "start_date": "2017-08-30", "completion_date": "2022-09-08", "has_results": true, "last_update_posted_date": "2023-10-23", "last_synced_at": "2026-09-21T05:05:03.149Z", "location_count": 120, "location_summary": "Dothan, Alabama • Madison, Alabama • Chandler, Arizona + 96 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Madison", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03439254" }, { "nct_id": "NCT04415151", "title": "Tofacitinib for Treatment of Moderate COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19 Pneumonia" ], "interventions": [ { "name": "Tofacitinib 10 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 24, "start_date": "2020-10-14", "completion_date": "2021-02-28", "has_results": true, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-09-21T05:05:03.149Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04415151" }, { "nct_id": "NCT07132177", "title": "Targeted Naltrexone to Support Individuals Participating in Dry January", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcohol Misuse" ], "interventions": [ { "name": "Naltrexone (oral tablets)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2025-11-03", "completion_date": "2026-04-01", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-09-21T05:05:03.149Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07132177" } ] }